Assessment of suitability of saxagliptin hydrochloride for development of controlled release parenteral formulation by preformulation studies
Keywords:
diabetes mellitus, parenteral formulation, preformulation, saxagliptin HCl, stabilityAbstract
The main objective of pre-formulation study is to develop the stable, elegant, safe and effective drug delivery system by establishing drug kinetic profile, formulation compatibility with different excipients and physico-chemical parameters of new drug molecules. This could provide key evidence for implementing formulation design or requirement of the molecular alteration. So, in the present study preformulation studies were performed on Saxagliptin Hydrochloride (SXG) to assess its suitability for parenteral formulation. SXG is a potent and selective reversible inhibitor of dipeptidyl peptidase-4 used to treat type –II diabetes mellitus. The authenticity of SXG was established by differential scanning calorimetry (DSC) and fourier transform infrared spectroscopy(FTIR) spectra. An ultraviolet–visible (UV) spectrophotometric and high performance liquid chromatography (HPLC) methods were employed for determination of SXG in bulk API (active pharmaceutical ingredient). The UV method was linear within the range of 1-40 μg/ml. The proposed methodology is robust which can be concluded from the lower percentage standard deviation percentage co efficient of variance (% CV) values of intraday and inter day variability. The retention time was observed 1.3 min of SXG in HPLC method. The higher regression coefficient value (0.999) indicates the methodology is robust.
Downloads
References
Behera, B., Sahoo, S., Dhal, S., Barik, B., & Gupta, B. (2008). Characterization of glipizide-loaded polymethacrylate microspheres prepared by an emulsion solvent evaporation method. Trop J Pharmaceut Res, 7(1), 879-885. DOI: https://doi.org/10.4314/tjpr.v7i1.14672
Chandira, R. M., Palanisamy, P., Jaykar, B., Venkateswarlu, B., & Pasupathi, A. (2013). Formulation and evaluation of Saxagliptin Immediate release and Metformin Hydrochloride Sustained release tablet. Int J Health Sci, 1(1), 37.
Fralick, M., Jenkins, A. J., Khunti, K., Mbanya, J. C., Mohan, V., & Schmidt, M. (2022). Global accessibility of therapeutics for diabetes mellitus. Nat Rev, 1-6. DOI: https://doi.org/10.1038/s41574-021-00621-y
Ghule, K. B., Dhobale, S. M., Kedar, V. D., & Jadhav, S. L. (2019). The Enhancement of solubility and dissolution rate of saxagliptine hydrochloride by solid dispersion technique. J DRUG DEV, 9(3), 393-396.
Gopinath, R., & Naidu, R. (2011). Pharmaceutical preformulation studies–current review. Int J Pharmaceut Biol Arch, 2(5), 1391-1400.
Madhavi, S., & Rani, A. P. (2017). Development and validation of a method for simultaneous determination of dapagliflozin and saxagliptin in a formulation by RP-UPLC. World J Pharma Res, 6(12), 904-916. DOI: https://doi.org/10.5958/0974-360X.2017.00796.X
Mao, S., Guo, C., Shi, Y., & Li, L. C. (2012). Recent advances in polymeric microspheres for parenteral drug delivery–part 1. Expet Opin Drug Deliv, 9(9), 1161-1176. DOI: https://doi.org/10.1517/17425247.2012.709844
Patra, P. S. K. (2012). Automatic diagnosis of diabetes by expert system. Int J Comput Sci, 9(2), 299.
Prasad, P., Satyanaryana, K., & Krishnamohan, G. (2015). Development and Validation of a Method for Simultaneous Determination of Metformin and Saxagliptin in a Formulation by RP-HPLC. Am J Anal Chem, 6(11), 841. DOI: https://doi.org/10.4236/ajac.2015.611080
Rasul, A., Maheen, S., Khan, H. U., Rasool, M., Shah, S., Abbas, G., . . . Asad, M. H. H. B. (2021). Formulation, Optimization, In Vitro and In Vivo Evaluation of Saxagliptin-Loaded Lipospheres for an Improved Pharmacokinetic Behavior. BioMed Research, 2021. DOI: https://doi.org/10.1155/2021/3849093
Rosenstock, J., Aguilar-Salinas, C., Klein, E., Nepal, S., List, J., & Chen, R. (2009). Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin, 25(10), 2401-2411. DOI: https://doi.org/10.1185/03007990903178735
Rother, K. (2007). Diabetes treatment—bridging the divide. New Engl J Med, 356(15), 1499. DOI: https://doi.org/10.1056/NEJMp078030
Tekkeli, S., Kızıltaş, M. V., & Dinçel, D. (2013). An HPLC method for the determination of saxagliptin in human plasma with fluorescence detection. J Adv Chem, 5(3), 43.
Verma, G., & Mishra, M. K. (2016). Pharmaceutical preformulation studies in formulation and development of new dosage form: A review. Int. J. Pharma Res. Rev, 5(10).
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
